和黄医药首席医学官石明:出海带动明星抗癌药销量大增,目标明年实现自给自足

时代周报
07 Dec 2024

本文来源:时代周报 作者:杜苏敏在与跨国药企武田制药就核心产品呋喹替尼达成合作后,创新药企和黄医药(00013.HK)进入快速发展期。呋喹替尼是和黄医药自主研发的首款抗癌新药,作为一款喹唑啉类小分子血管生成抑制剂,其主要作用靶点是VEGFR激酶家族(VEGFR1、2和3),用于治疗晚期结直肠癌。2018年,呋喹替尼(国内商品名:爱优特)获国家药监局批准上市,用于结直肠癌的三线治疗。2023年1月,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10